Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ROCKVILLE, Md., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that earlier today it sued generic drug makers Actavis Inc., Watson Laboratories, Inc. – Florida, Actavis Pharma, Inc., Watson Laboratories, Inc., and Anda, Inc. (collectively "Watson") for infringement of two patents covering its antiepileptic drug Oxtellar XR™. Supernus's United States Patent Nos. 7,722,898 and 7,910,131 cover once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. Both patents do not expire until April 13, 2027.
Help employers find you! Check out all the jobs and post your resume.
ROCKVILLE, Md., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that earlier today it sued generic drug makers Actavis Inc., Watson Laboratories, Inc. – Florida, Actavis Pharma, Inc., Watson Laboratories, Inc., and Anda, Inc. (collectively "Watson") for infringement of two patents covering its antiepileptic drug Oxtellar XR™. Supernus's United States Patent Nos. 7,722,898 and 7,910,131 cover once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. Both patents do not expire until April 13, 2027.
Help employers find you! Check out all the jobs and post your resume.
